Encapsulation of benznidazole in nanostructured lipid carriers and increased trypanocidal activity in a resistant Trypanosoma cruzi strain

Encapsulation of benznidazole in nanostructured lipid carriers and increased trypanocidal activity in a resistant Trypanosoma cruzi strain

Abstract Chagas disease is a neglected parasitic disease caused by Trypanosoma cruzi, whose treatment has remained unsatisfactory for over 50 years, given that it is limited to two drugs. Benznidazole (BZN) is an efficient antichagasic drug used as the first choice, although its poor water-solubilit...

Full description

Bibliographic Details
Main Authors:	Flávia Lidiane Oliveira da Silva, Maria Betânia de Freitas Marques, Maria Irene Yoshida, Wagner da Nova Mussel, João Vinícios Wirbitzki da Silveira, Poliana Ribeiro Barroso, Kelly Cristina Kato, Helen Rodrigues Martins, Guilherme Carneiro
Format:	Article
Language:	English
Published:	Universidade de São Paulo 2023-05-01
Series:	Brazilian Journal of Pharmaceutical Sciences
Subjects:	Drug delivery systems Lipid nanoparticles Nanomedicine Neglected diseases Poorly water-soluble drugs Thermal analysis.
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502023000100356&lng=en&tlng=en

Similar Items

Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains
by: Veloso VM, et al.
Published: (2001-01-01)

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease
by: Daniele Cavalcante Gomes, et al.
Published: (2023-09-01)

Molecular characterization of the hexose transporter gene in benznidazole resistant and susceptible populations of <it>Trypanosoma cruzi</it>
by: dos Santos Paula F, et al.
Published: (2012-08-01)

Antiparasitic Activity of <i>Hippeastrum</i> Species and Synergistic Interaction between Montanine and Benznidazole against <i>Trypanosoma cruzi</i>
by: Mauricio Piñeiro, et al.
Published: (2023-01-01)

Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease
by: Margoth Moreno, et al.
Published: (2010-11-01)

Overexpression of eukaryotic initiation factor 5A (eIF5A) affects susceptibility to benznidazole in Trypanosoma cruzi populations
by: Douglas de Souza Moreira, et al.
Published: (2018-07-01)

The level of ascorbate peroxidase is enhanced in benznidazole-resistant populations of Trypanosoma cruzi and its expression is modulated by stress generated by hydrogen peroxide
by: Fernanda Barbosa Nogueira, et al.
Published: (2012-06-01)

Trypanocide usage in the cattle belt of southwestern Uganda
by: Keneth Iceland Kasozi, et al.
Published: (2023-12-01)

Library of Selenocyanate and Diselenide Derivatives as In Vivo Antichagasic Compounds Targeting <i>Trypanosoma cruzi</i> Mitochondrion
by: Rubén Martín-Escolano, et al.
Published: (2021-05-01)

Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
by: Davi Alvarenga Lima, et al.
Published: (2023-05-01)

Benznidazole Treatment: Time- and Dose-Dependence Varies with the <i>Trypanosoma cruzi</i> Strain
by: Kátia da Silva Fonseca, et al.
Published: (2021-06-01)

Development of Artificial Plasma Membranes Derived Nanovesicles Suitable for Drugs Encapsulation
by: Carolina Martinelli, et al.
Published: (2020-07-01)

Effect of benznidazole on cerebral microcirculation during acute Trypanosoma cruzi infection in mice
by: Beatriz Matheus Souza Gonzaga, et al.
Published: (2022-12-01)

Evaluation of in vitro anti-Trypanosoma cruzi activity of medications benznidazole, amiodarone hydrochloride, and their combination
by: Angela Maria Lourenço, et al.

Synthesis, Characterization, and Acute Cytotoxicity Evaluation of Chloroquine Encapsulating Liposomes
by: Nathan D. Donahue, et al.
Published: (2023-01-01)

Influence of the Encapsulation Efficiency and Size of Liposome on the Oral Bioavailability of Griseofulvin-Loaded Liposomes
by: Sandy Gim Ming Ong, et al.
Published: (2016-08-01)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
by: Elena Aguilera, et al.

A novel ABCG-like transporter of Trypanosoma cruzi is involved in natural resistance to benznidazole
by: Bianca Zingales, et al.
Published: (2015-05-01)

Solid Lipid Nanoparticles Enhancing the Leishmanicidal Activity of Delamanid
by: Javier Santamaría-Aguirre, et al.
Published: (2023-12-01)

Nanoconjugation and Encapsulation Strategies for Improving Drug Delivery and Therapeutic Efficacy of Poorly Water-Soluble Drugs
by: Thao T. D. Tran, et al.
Published: (2019-07-01)

Apoferritin and Apoferritin-Capped Metal Nanoparticles Inhibit Arginine Kinase of <i>Trypanosoma</i> <i>brucei</i>
by: Oluyomi Stephen Adeyemi, et al.
Published: (2020-07-01)

<i>Trypanosoma cruzi</i> Genome 15 Years Later: What Has Been Accomplished?
by: Jose Luis Ramirez
Published: (2020-08-01)

In vitro and in silico analysis of imatinib analogues as anti-Trypanosoma cruzi drug candidates
by: Luca S. F. Nesic de Freitas, et al.
Published: (2023-04-01)

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
by: Maria Katarine Costa Lucas Gontijo, et al.
Published: (2020-01-01)

In Vitro and In Vivo Trypanocidal Efficacy of Synthesized Nitrofurantoin Analogs
by: Linous Munsimbwe, et al.
Published: (2021-06-01)

Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
by: Shi Su, et al.
Published: (2020-09-01)

In Vivo Efficacy of Curcumin and Curcumin Nanoparticle in <i>Trypanosoma congolense</i>, Broden 1904 (Kinetoplastea: Trypanosomatidae)-Infected Mice
by: Nthatisi Innocentia Molefe-Nyembe, et al.
Published: (2023-10-01)

Glutamine metabolism modulates azole susceptibility in Trypanosoma cruzi amastigotes
by: Peter C Dumoulin, et al.
Published: (2020-12-01)

Intrinsic and Chemotherapeutic Stressors Modulate ABCC-Like Transport in <i>Trypanosoma cruzi</i>
by: Kelli Monteiro da Costa, et al.
Published: (2021-06-01)

Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability
by: Maria Rosa Gigliobianco, et al.
Published: (2018-08-01)

Nanodelivery systems: An efficient and target‐specific approach for drug‐resistant cancers
by: Sumel Ashique, et al.
Published: (2023-09-01)

Lawsone encapsulated polylactic‐co‐glycolic acid nanoparticles modified with chitosan‐folic acid successfully inhibited cell growth and triggered apoptosis in Panc‐1 cancer cells
by: Helia Ghafaripour, et al.
Published: (2023-07-01)

Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure
by: Fernando J Sánchez-Valdéz, et al.
Published: (2018-03-01)

Piplartine-Inspired 3,4,5-Trimethoxycinnamates: Trypanocidal, Mechanism of Action, and In Silico Evaluation
by: Carlos S. M. B. Filho, et al.
Published: (2023-06-01)

Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display.
by: Luis Antonio Rodriguez Carnero, et al.
Published: (2023-01-01)

Nano based drug delivery systems: recent developments and future prospects
by: Jayanta Kumar Patra, et al.
Published: (2018-09-01)

Trypanosoma cruzi iron superoxide dismutases: insights from phylogenetics to chemotherapeutic target assessment
by: Jéssica Hickson, et al.
Published: (2022-06-01)

Innovative nanocompounds for cutaneous administration of classical antifungal drugs: a systematic review
by: Rafael Silva Santos, et al.
Published: (2019-08-01)

New Approaches in Nanomedicine for Ischemic Stroke
by: Clara Correa-Paz, et al.
Published: (2021-05-01)

Development of multifunctional drug delivery systems based on virus-like nanoparticles for cancer targeting drug delivery
by: Biabanikhankahdani, Roya
Published: (2017)